What class of compound is MOTS-c?

MOTS-c is classified as a Mitochondrially-encoded peptide. Within this class, alternative names and analogues include Mitochondrial Open Reading Frame of the 12S rRNA Type-c. The class-level pharmacology shapes both the clinical applications and the safety profile; the protocol / scheduling / cycling literature treats MOTS-c alongside its class peers when evaluating relative merits.

How should MOTS-c be stored and reconstituted?

Lyophilised MOTS-c stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

Is MOTS-c safe during pregnancy or breastfeeding?

MOTS-c, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

How long until I see results from MOTS-c?

Acute effects from MOTS-c appear within hours of dosing for receptor-level changes. scheduling and cycle endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Home/ Compounds/ MOTS-c

MOTS-c

Protocol

Scheduling MOTS-c alongside existing protocols, training, and lifestyle inputs requires understanding the compound's pharmacokinetic constraints and the cycle calendar. A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity. Daily timing relative to meals and training, weekly cycle structure, and integration with stack components on independent pathways are the three layers of the protocol calendar developed below.

Protocol / Scheduling / Cycling Applications

Cycle DesignWeekly TimingDaily TimingCycle LengthPeriodised Cycles

Key Takeaways

Scheduling lens: MOTS-c's Hours; tissue-distributed half-life via subq places it in the multi-daily-dosing bucket.
Mechanism: Translocates to the nucleus under metabolic stress and activates AMPK signalling.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Translocates to the nucleus under metabolic stress and activates AMPK signalling. Improves insulin sensitivity, increases mitochondrial biogenesis, and protects against age-related muscle metabolic decline. Levels decline with age. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for MOTS-c.

Daily and weekly timing

MOTS-c with a Hours; tissue-distributed half-life pharmacokinetic profile sits in the multiple-daily-dosing bucket. The schedule is best built around either 2-3x weekly SubQ, with consistency mattering more than the absolute clock time of any single dose.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any MOTS-c protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most MOTS-c schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Stack scheduling with other compounds

When MOTS-c is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Multiple subcutaneous compounds can be combined in a single injection where compatible, or staggered through the day where pharmacokinetics differ meaningfully. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.

Protocol / Scheduling / Cycling Applications

Wash-Out

Schedule design for MOTS-c in wash-out starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Multi-Peptide Timing

The most-asked scheduling question for MOTS-c in multi-peptide timing is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Cycle Length

For cycle length scheduling, MOTS-c is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Stack Scheduling

Schedule design for MOTS-c in stack scheduling starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	1-10 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1-10 mg	4–6 weeks initial cycle
Protocol focus	SubQ	1-10 mg	2-3x weekly SubQ
Maintenance phase	SubQ	1-10 mg	Ongoing with periodic pauses

Dose timing for MOTS-c is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

MOTS-c stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

MOTS-c + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with MOTS-c's mechanism in protocol / scheduling / cycling protocols.
MOTS-c + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with MOTS-c's mechanism in protocol / scheduling / cycling protocols.
MOTS-c + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with MOTS-c's mechanism in protocol / scheduling / cycling protocols.
MOTS-c + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with MOTS-c's mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not specifically listed FDA: Unapproved Research: Animal + early human

Excellent in animal studies. Limited human data. Watch hypoglycaemia in users on insulin/sulfonylureas.

Lens-specific safety considerations for protocol / scheduling / cycling use of MOTS-c: Excellent in animal studies. Limited human data. Watch hypoglycaemia in users on insulin/sulfonylureas. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

MOTS-c — mitochondrial peptide regulator of metabolism

PMID 25738459

Supporting

MOTS-c in aging and metabolic disease

PMID 29748417

MOTS-c vs Related Peptides

Compound	Profile	Onset	Best For
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

Daily timing for MOTS-c?

Pragmatic timing depends on pharmacokinetics: multi-daily dosing for short half-life. Consistent timing matters more than the absolute clock time of any single dose.

Cycle length and off-cycle period?

Standard cycle for MOTS-c is 8–12 weeks on, 4 weeks off. Longer cycles produce diminishing returns and increased downregulation risk; shorter cycles undershoot the response window. The 4-week off-period is functionally required for receptor reset rather than optional.

Stack timing relative to training and meals?

Fasted dosing for GH-axis and AMPK-engaging compounds; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it. Training-day-only versus daily dosing depends on the compound and the volume of training; verify against the specific protocol.

What is the mechanism of action of MOTS-c?

Translocates to the nucleus under metabolic stress and activates AMPK signalling. Improves insulin sensitivity, increases mitochondrial biogenesis, and protects against age-related muscle metabolic decline. Levels decline with age. For scheduling and cycle applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Translocates to the nucleus under metabolic stress and activates AMPK signalling. The protocol / scheduling / cycling interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What are the safety considerations for MOTS-c?

Excellent in animal studies. Limited human data. Watch hypoglycaemia in users on insulin/sulfonylureas. For scheduling and cycle use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. MOTS-c's Hours; tissue-distributed pharmacokinetic profile and subq administration route influence the side-effect profile in predictable ways.

Clinical Protocol

Start a MOTS-c Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified MOTS-c and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 2174 Da
Sequence length: 16 aa
Half-life: Hours; tissue-distributed
WADA: Not specifically listed
FDA: Unapproved
Research: Animal + early human

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for MOTS-c unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for MOTS-c

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised